X4 Pharmaceuticals, Inc (XFOR) Executive Compensation
X4 Pharmaceuticals, Inc (XFOR) is a publicly traded company on the Nasdaq, categorized under SIC 2836 (Biological Products, (No Diagnostic Substances)). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: XFOR
CIK: 1501697
Exchange: Nasdaq
SIC 2836: Biological Products, (No Diagnostic Substances)
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
PricewaterhouseCoopers LLP
Auditor SinceSince 12/31/2016 12:00:00 AM
Lead Engagement PartnerHolly Reeves
Audit LocationBoston, Massachusetts, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-10-08 | 2026-10-07 | 8-K | 0001501697-26-000081 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-10-07 | — | SCHEDULE 13G/A Filing | 0000315066-26-002326 | View SEC Doc Filr Page |
| 4 | 2026-10-05 | 2026-10-01 | FORM 4 | 0001501697-26-000078 | View SEC Doc Filr Page |
| 144 | 2026-10-01 | — | 144 Filing | 0001276750-26-000008 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-09-21 | — | SCHEDULE 13G Filing | 0001738048-26-000071 | View SEC Doc Filr Page |
| 8-K | 2026-09-09 | 2026-09-08 | 8-K | 0001501697-26-000076 | View SEC Doc Filr Page |
| 8-K | 2026-09-08 | 2026-09-08 | 8-K | 0001501697-26-000072 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001193125-26-352651 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001172661-26-003487 | View SEC Doc Filr Page |
| 4 | 2026-08-13 | 2026-08-12 | FORM 4 | 0001501697-26-000070 | View SEC Doc Filr Page |
| 4 | 2026-08-13 | 2026-08-12 | FORM 4 | 0001501697-26-000069 | View SEC Doc Filr Page |
| 144 | 2026-08-13 | — | 144 Filing | 0002081729-26-000004 | View SEC Doc Filr Page |
| 144 | 2026-08-13 | — | 144 Filing | 0001339498-26-000003 | View SEC Doc Filr Page |
| 10-Q | 2026-08-06 | 2026-06-30 | 10-Q | 0001501697-26-000068 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-07-30 | — | SCHEDULE 13G Filing | 0002012383-26-003133 | View SEC Doc Filr Page |
| 4 | 2026-07-01 | 2026-06-30 | FORM 4 | 0001501697-26-000065 | View SEC Doc Filr Page |
| 4 | 2026-07-01 | 2026-07-01 | FORM 4 | 0001501697-26-000064 | View SEC Doc Filr Page |
| 3 | 2026-07-01 | 2026-07-01 | FORM 3 | 0001501697-26-000063 | View SEC Doc Filr Page |
| 8-K | 2026-07-01 | 2026-06-30 | 8-K | 0001501697-26-000060 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0001193125-26-226568 | View SEC Doc Filr Page |
| EFFECT | 2026-05-14 | — | EFFECT Filing | 9999999995-26-001669 | View SEC Doc Filr Page |
| 8-K/A | 2026-05-13 | 2026-05-11 | 8-K/A | 0001501697-26-000051 | View SEC Doc Filr Page |
| 4 | 2026-05-13 | 2026-05-12 | FORM 4 | 0001501697-26-000049 | View SEC Doc Filr Page |
| 144 | 2026-05-12 | — | 144 Filing | 0001276750-26-000004 | View SEC Doc Filr Page |
| 8-K | 2026-05-12 | 2026-05-11 | 8-K | 0001501697-26-000047 | View SEC Doc Filr Page |